Macrophage Therapeutics Inc., of Dublin, Ohio, a subsidiary of Navidea Biopharmaceuticals Inc., reported it executed definitive agreements for its previously announced $2.5 million round of standalone financing, led by Platinum-Montaur Life Sciences and Michael Goldberg, CEO of Macrophage.